Highlights BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Delayed London S.E. Other stock markets 02:59:59 2024-05-21 am EDT			5-day change	1st Jan Change
10 ^GBX	0.00%		-13.04%	-4.76%

Apr. 17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
Apr. 17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	Apr. 17	MT
Bivictrix selects final sequences for lead tumour programme	Nov. 30	AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	Nov. 30	CI
BiVictriX patent boost; 4Global deal extended	Nov. 15	AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	Nov. 15	MT
Bivictrix says BVX001 increases survival rates by more than double	23-10-12	AN
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	23-10-03	CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	23-10-03	CI
AEW UK REIT appoints new chair; Oberon raises money	23-09-19	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	23-09-19	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-19	CI
Bivictrix Therapeutics granted US patent for cancer drug BVX001	23-08-23	AN
BiVictriX Therapeutics Secures US Patent for Lead Asset	23-08-23	MT
EARNINGS UPDATES: Ironveld sees interim pretax loss widen on costs	23-03-30	AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Reports FY22 Loss GBX-3.78	23-03-30	MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
TRADING UPDATES: Bivictrix hails cancer therapy candidate	23-01-31	AN
BiVictriX Therapeutics Plc Announces Positive Data from Preclinical Study of BVX001	23-01-31	CI
AIM WINNERS & LOSERS: Bivictrix surges on lead for BVX001 programme	22-12-07	AN
Bivictrix identifies lead for antibody drug conjugates programme	22-12-07	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Highlights

Filters